Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230956 · ClinicalTrials.gov registry record · Phase 2

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

A Phase 2 study, sponsored by Allergan.

Completed
Registry status
Phase 2
Development phase
176
Enrollment target

NCT02230956: Completed Phase 2 study, sponsored by Allergan.

NCT02230956 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 176 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230956, a Phase 2 study, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 2
Development phase
176 participants
Enrollment target

Study Summary

This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.

Primary Outcome

Participants recorded the pain in their knee during the previous 24 hours in a daily diary where: 0=no pain to 10= worst pain possible. The daily pain scores over 7-days were averaged. A negative change from Baseline indicates improvement.

Interventions

  • DRUG Normal Saline
  • BIOLOGICAL onabotulinumtoxinA

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2014-10
Est. Completion 2016-03
Phase Phase 2
Allergan

314 total trials

What the finished NCT02230956 record still lists

NCT02230956 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).

The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.

NCT02230956 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02230956 about?

NCT02230956 is a clinical study titled "BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis". This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.

What is the current status of trial NCT02230956?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2014-10. Estimated completion is 2016-03.

What interventions are being tested in trial NCT02230956?

The interventions under investigation include: Normal Saline (DRUG), onabotulinumtoxinA (BIOLOGICAL).

Who is sponsoring clinical trial NCT02230956?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02230956's enrollment target sits among peer trials

176 394th of 2000 higher than 1,605 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03304821 · 176 participants · Phase 2

    Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

  • NCT03447938 · 176 participants · NA

    The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

  • NCT03824145 · 176 participants · NA

    Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

  • NCT04177914 · 176 participants · Phase 3

    HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02230956, the US trial registry maintained by the National Library of Medicine. NCT02230956 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.